PanGen Biotech Inc. (KOSDAQ:222110)
South Korea · Delayed Price · Currency is KRW 6,180.00
+130.00 (2.15%)
Last updated: Aug 6, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 14,639 | 14,673 | 7,315 | 6,501 | 7,936 | 6,191 | Upgrade |
Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade |
| 14,639 | 14,673 | 7,315 | 6,501 | 7,936 | 6,191 | Upgrade | |
Revenue Growth (YoY) | 45.57% | 100.58% | 12.53% | -18.08% | 28.18% | 114.87% | Upgrade |
Cost of Revenue | 8,904 | 9,534 | 6,343 | 5,858 | 7,420 | 4,838 | Upgrade |
Gross Profit | 5,735 | 5,139 | 971.8 | 642.47 | 515.69 | 1,353 | Upgrade |
Selling, General & Admin | 1,769 | 1,768 | 1,536 | 1,272 | 969.85 | 1,108 | Upgrade |
Research & Development | 1,983 | 2,012 | 3,332 | 3,850 | 2,734 | 3,676 | Upgrade |
Other Operating Expenses | 27.54 | 26.32 | 26.64 | 25.92 | 28 | 34.25 | Upgrade |
Operating Expenses | 4,094 | 4,118 | 5,197 | 5,233 | 3,804 | 5,053 | Upgrade |
Operating Income | 1,640 | 1,020 | -4,225 | -4,591 | -3,288 | -3,700 | Upgrade |
Interest Expense | -270.72 | -322.1 | -220.68 | -128.77 | -293.25 | -1,013 | Upgrade |
Interest & Investment Income | 272.14 | 184.78 | 41.75 | 246.57 | 179.7 | 255.54 | Upgrade |
Currency Exchange Gain (Loss) | 94.02 | 172.79 | 12.47 | 7.34 | 92.88 | -83.99 | Upgrade |
Other Non Operating Income (Expenses) | -91.79 | -91.66 | -64.6 | 37.97 | 59.88 | 185.79 | Upgrade |
EBT Excluding Unusual Items | 1,644 | 963.97 | -4,457 | -4,428 | -3,249 | -4,356 | Upgrade |
Gain (Loss) on Sale of Assets | 16.78 | 13.77 | 15.15 | -0.24 | -0.67 | -0.03 | Upgrade |
Other Unusual Items | 25.85 | 25.85 | - | -7.39 | - | - | Upgrade |
Pretax Income | 1,687 | 1,004 | -4,441 | -4,435 | -3,250 | -4,356 | Upgrade |
Income Tax Expense | 73.53 | 59.9 | 47.43 | 58.69 | 60.5 | - | Upgrade |
Net Income | 1,613 | 943.69 | -4,489 | -4,494 | -3,310 | -4,356 | Upgrade |
Net Income to Common | 1,613 | 943.69 | -4,489 | -4,494 | -3,310 | -4,356 | Upgrade |
Shares Outstanding (Basic) | 12 | 11 | 11 | 11 | 10 | 10 | Upgrade |
Shares Outstanding (Diluted) | 12 | 11 | 11 | 11 | 10 | 10 | Upgrade |
Shares Change (YoY) | 10.08% | 7.03% | 0.13% | 4.47% | 6.02% | -0.04% | Upgrade |
EPS (Basic) | 135.74 | 82.49 | -420.00 | -421.00 | -324.00 | -452.00 | Upgrade |
EPS (Diluted) | 135.74 | 82.49 | -420.00 | -421.00 | -324.00 | -452.00 | Upgrade |
Free Cash Flow | 2,067 | 2,627 | -3,873 | -4,231 | -4,749 | -5,437 | Upgrade |
Free Cash Flow Per Share | 173.96 | 229.63 | -362.36 | -396.34 | -464.83 | -564.12 | Upgrade |
Gross Margin | 39.17% | 35.02% | 13.29% | 9.88% | 6.50% | 21.86% | Upgrade |
Operating Margin | 11.21% | 6.95% | -57.76% | -70.62% | -41.44% | -59.77% | Upgrade |
Profit Margin | 11.02% | 6.43% | -61.36% | -69.13% | -41.72% | -70.36% | Upgrade |
Free Cash Flow Margin | 14.12% | 17.90% | -52.94% | -65.08% | -59.85% | -87.81% | Upgrade |
EBITDA | 3,095 | 2,489 | -2,629 | -2,987 | -1,756 | -2,132 | Upgrade |
EBITDA Margin | 21.14% | 16.96% | -35.94% | -45.96% | -22.13% | -34.44% | Upgrade |
D&A For EBITDA | 1,455 | 1,468 | 1,597 | 1,603 | 1,532 | 1,568 | Upgrade |
EBIT | 1,640 | 1,020 | -4,225 | -4,591 | -3,288 | -3,700 | Upgrade |
EBIT Margin | 11.21% | 6.95% | -57.76% | -70.62% | -41.44% | -59.77% | Upgrade |
Effective Tax Rate | 4.36% | 5.97% | - | - | - | - | Upgrade |
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.